Elizabeth A. Ashley
A5078711287- Malaria Research and Control
- Mosquito-borne diseases and control
- Computational Drug Discovery Methods
- Antibiotic Use and Resistance
- Antibiotic Resistance in Bacteria
- Bacterial Identification and Susceptibility Testing
- Drug-Induced Hepatotoxicity and Protection
- Parasites and Host Interactions
- Viral Infections and Vectors
- Global Maternal and Child Health
- Travel-related health issues
- Research on Leishmaniasis Studies
- Trypanosoma species research and implications
- Pharmacological Effects and Toxicity Studies
- Pneumonia and Respiratory Infections
- Burkholderia infections and melioidosis
- HIV/AIDS drug development and treatment
- Drug Transport and Resistance Mechanisms
- Vector-borne infectious diseases
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Urinary Tract Infections Management
- Genetics, Bioinformatics, and Biomedical Research
- Sepsis Diagnosis and Treatment
- vaccines and immunoinformatics approaches
University of Oxford
2016-2025
Mahosot Hospital
2019-2025
Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit
2019-2025
Angkor Hospital for Children
2010-2024
Wellcome Trust
2020-2024
Mahidol Oxford Tropical Medicine Research Unit
2014-2023
Mahidol University
2014-2023
Participatory Development Training Centre
2022
Willis Towers Watson (United Kingdom)
2022
Churchill Hospital
2007-2021
Artemisinin resistance in Plasmodium falciparum has emerged Southeast Asia and now poses a threat to the control elimination of malaria. Mapping geographic extent is essential for planning containment strategies.Between May 2011 April 2013, we enrolled 1241 adults children with acute, uncomplicated malaria an open-label trial at 15 sites 10 countries (7 3 Africa). Patients received artesunate, administered orally daily dose either 2 mg per kilogram body weight day or 4 kilogram, days,...
Artemisinin resistance in Plasmodium falciparum threatens global efforts to control and eliminate malaria. Polymorphisms the kelch domain-carrying protein K13 are associated with artemisinin resistance, but underlying molecular mechanisms unknown. We analyzed vivo transcriptomes of 1043 P. isolates from patients acute malaria found that is increased expression unfolded response (UPR) pathways involving major PROSC TRiC chaperone complexes. Artemisinin-resistant parasites also exhibit...
BackgroundEmergence of artemisinin resistance in southeast Asia poses a serious threat to the global control Plasmodium falciparum malaria. Discovery K13 marker has transformed approaches monitoring resistance, allowing introduction molecular surveillance remote areas through analysis DNA. We aimed assess spread artemisinin-resistant P Myanmar by determining relative prevalence parasites carrying K13-propeller mutations.MethodsWe did this cross-sectional survey at malaria treatment centres...
Evolving resistance to artemisinin-based compounds threatens derail attempts control malaria. Resistance has been confirmed in western Cambodia and recently emerged Thailand, but is absent from neighboring Laos. Artemisinin results reduced parasite clearance rates (CRs) after treatment. We used a two-phase strategy identify genome region(s) underlying this ongoing selective event. Geographical differentiation haplotype structure at 6969 polymorphic single-nucleotide polymorphisms (SNPs) 91...
The emergence and spread of resistance in Plasmodium falciparum malaria to artemisinin combination therapies the Greater Mekong subregion poses a major threat control elimination. current study is part multi-country, open-label, randomised clinical trial (TRACII, 2015-18) evaluating efficacy, safety, tolerability triple therapies. A very high rate treatment failure after with dihydroartemisinin-piperaquine was observed Thailand, Cambodia, Vietnam. immediate public health importance our...
Background Artemisinin combination treatments (ACT) are recommended as first line treatment for falciparum malaria throughout the affected world. We reviewed efficacy of a 3-day regimen mefloquine and artesunate (MAS3), over 13 year period continuous deployment first-line in camps displaced persons clinics migrant population along Thai-Myanmar border. Methods Findings 3,264 patients were enrolled prospective trials between 1995 2007 treated with MAS3. The proportion parasitaemia persisting...
The effects of malaria and its treatment in the first trimester pregnancy remain an area concern. We aimed to assess outcome malaria-exposed malaria-unexposed first-trimester pregnancies women from Thai-Burmese border compare outcomes after chloroquine-based, quinine-based, or artemisinin-based treatments.We analysed all antenatal records attending Shoklo Malaria Research Unit clinics May 12, 1986, Oct 31, 2010. Women without were compared with those who had a single episode trimester....
Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment delay emergence of antimalarial resistance.
Background. Deployment of mefloquine–artesunate (MAS3) on the Thailand–Myanmar border has led to a sustained reduction in falciparum malaria, although antimalarial efficacy declined substantially recent years. The role Plasmodium K13 mutations (a marker artemisinin resistance) reducing treatment remains controversial. Methods. Between 2003 and 2013, we studied MAS3 1005 patients with uncomplicated P. malaria relation molecular markers resistance. Results. Polymerase chain reaction...
MalariaGEN is a data-sharing network that enables groups around the world to work together on genomic epidemiology of malaria. Here we describe new release curated genome variation data 7,000 Plasmodium falciparum samples from partner studies in 28 malaria-endemic countries. High-quality genotype calls 3 million single nucleotide polymorphisms (SNPs) and short indels were produced using standardised analysis pipeline. Copy number variants associated with drug resistance structural cause...
The Greater Mekong subregion is a recurrent source of antimalarial drug resistance in Plasmodium falciparum malaria. This study aimed to characterise the extent and spread across this entire region between 2007 2018.
<ns3:p>We describe the MalariaGEN Pf7 data resource, seventh release of <ns3:italic>Plasmodium falciparum</ns3:italic> genome variation from network. It comprises over 20,000 samples 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For first time we include dried blood spot sequenced after selective whole amplification, necessitating new methods to genotype copy number variations. We identify a large newly emerging...
Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their activities in patients have not been compared directly. The aim of this ongoing platform trial is to compare different treatments using rate viral clearance as measure effect.
Enteric fever, a systemic infection caused by Salmonella enterica serovars Typhi and Paratyphi A, remains major cause of morbidity mortality in low-income middle-income countries. fever is preventable through the provision clean water adequate sanitation can be successfully treated with antibiotics. However, high levels antimicrobial resistance (AMR) compromise effectiveness treatment. We provide estimates prevalence AMR S A 75 endemic countries, including 30 locations without data.